Seqirus UK Limited Sustainability Profile
Seqirus UK Limited, a prominent player in the biopharmaceutical industry, is headquartered in Great Britain. Established as a subsidiary of CSL Limited, Seqirus focuses on the development and distribution of innovative vaccines and immunotherapy solutions. With a strong presence in Europe and North America, the company has made significant strides since its founding in 2015, particularly in the field of influenza vaccines. Seqirus is renowned for its unique product offerings, including the adjuvanted flu vaccine, which enhances immune response, setting it apart in a competitive market. The company has achieved notable milestones, such as being one of the largest influenza vaccine manufacturers globally. With a commitment to public health and a robust pipeline of vaccine candidates, Seqirus continues to solidify its position as a leader in the vaccine industry.
DitchCarbon Score
How does Seqirus UK Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Seqirus UK Limited's score of 41 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Seqirus UK Limited, headquartered in Great Britain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of CSL Limited, which cascades its climate commitments and targets down to Seqirus. While Seqirus UK Limited does not have its own documented reduction targets, it aligns with the broader sustainability initiatives of CSL Limited. This includes commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which are managed at the parent company level. As a part of its corporate family, Seqirus is expected to adhere to the climate strategies and performance metrics set by CSL Limited, which may include significant reduction targets aimed at minimising carbon footprints across all scopes of emissions. However, specific details regarding these targets or achievements have not been disclosed for Seqirus UK Limited. In summary, while Seqirus UK Limited does not provide its own emissions data or reduction targets, it is integrated into the climate commitments of CSL Limited, reflecting a commitment to sustainability within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 250,000,000 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 58,000,000 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - |
How Carbon Intensive is Seqirus UK Limited's Industry?
How Carbon Intensive is Seqirus UK Limited's Location?
Seqirus UK Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Seqirus UK Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
